JAZZ News and Press, Jazz Pharmaceuticals plc From 04/06/22

Following three consecutive sessions of gains, Jazz Pharmaceuticals (NASDAQ:JAZZ -3.3%) is trading lower in the morning hours Wednesday after Morgan Stanley downgraded the neurology-focused pharma company citing the recent outperformance in its shares. Noting that Jazz (JAZZ) has climbed more...

Biotech stocks, in general, again performed dismally in the first quarter of 2022. However, there are some signs of improvement. The lower valuations could present a great buying opportunity once the inevitable strong rebound materializes. We asked three Motley Fool contributors which b...

Jazz Pharmaceuticals (NASDAQ: JAZZ) , which specializes in neuroscience and oncology therapies, saw its stock rise 13.3% in March, according to data from S&P Global Market Intelligence . The stock began the month at $135.93 and never looked back, climbing to a high of $162.7...

The world is abuzz once again with interest in cannabis stocks thanks to the continuing legislative momentum of critical bills now making their way through Congress. The Marijuana Opportunity, Reinvestment and Expungement Act (the “MORE Act”) is a bill sponsored by House Judicia...

Jazz Pharmaceuticals to Participate in Upcoming April Investor Conferences PR Newswire DUBLIN , March 29, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the following upcoming investor con...

The shares of Axsome Therapeutics (NASDAQ:AXSM +12.9%) have reached the highest level since November after Truist Securities raised the price target of the clinical-stage pharma company on Tuesday, citing its deal to acquire Sunosi (solriamfetol) from Jazz Pharmaceuticals (JAZZ +0.4%). S...

Apple (NASDAQ:AAPL) took the spotlight in Monday's pre-market trading. The company won a Best Picture Oscar, but shares lost ground amid reports that it is cutting back production of certain products. Tesla (TSLA) represented another big name garnering attention before the bell. Shares of Elo...

Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics PR Newswire Jazz to receive $53 million upfront cash payment, and royalty rights Transaction designed to ensure uninterrupted patient access to Sunosi ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) and its subsidiary, GW Pharmaceuticals (OTCPK:GWPRF) announced the official initiation of construction of its new, state-of-the-art manufacturing facility at Kent Science Park (KSP) in Sittingbourne. The construction begins on a new state-of-the-art manufact...

Jazz Pharmaceuticals (NASDAQ:JAZZ) said the first patient was enrolled in a phase 2 trial evaluating Zepzelca (lurbinectedin) as a monotherapy in three groups: patients with advanced urothelial carcinoma, large cell neuroendocrine carcinoma of the lung, or homologous recombination deficient (...